家族史与胚系遗传风险单核苷酸多态性对有利风险前列腺癌长期结局的影响
基于卫生专业人员随访研究1986至2017年诊断的1367例低危或有利中危前列腺癌患者,评估前列腺、乳腺和/或胰腺癌家族史及胚系风险单核苷酸多态性(SNP)与前列腺癌特异性死亡的关联。中位随访14.9年,阳性家族史与前列腺癌特异性死亡风险升高相关(HR 1.95,95%CI 1.15-3.32,P=.014),rs2735839风险等位基因亦相关(HR 1.81,95%CI 1.04-3.17,P=.037),多基因风险评分无显著关联。
要点
- 有利风险前列腺癌患者中,前列腺、乳腺和/或胰腺癌家族史阳性者前列腺癌特异性死亡风险升高(HR 1.95)。
- rs2735839(19q13)风险等位基因与前列腺癌特异性死亡相关(HR 1.81/风险等位基因)。
- 家族史与rs2735839风险等位基因对前列腺癌特异性死亡呈加性风险(HR 1.78/风险因素)。
核心结论
- 前列腺、乳腺或胰腺癌家族史和/或19q13胚系风险等位基因与有利风险患者前列腺癌特异性死亡风险升高相关。
- 这些发现对家族史和胚系遗传风险SNP应如何纳入有利风险前列腺癌的临床决策具有意义。
研究设计与样本
- 前瞻性卫生专业人员随访研究(Health Professionals Follow-up Study)中1986至2017年诊断的1367例低危或有利中危前列腺癌参与者,接受全基因组SNP基因分型。
- 采用多变量Cox回归评估家族史、特定胚系风险变异及269个SNP的多基因风险评分与前列腺癌特异性死亡的关联。
主要发现
- 489例(36%)参与者有前列腺、乳腺和/或胰腺癌家族史。
- 自诊断起中位随访14.9年,有阳性家族史的有利风险前列腺癌患者前列腺癌特异性死亡风险显著高于无任何家族史者(HR 1.95,95%CI 1.15-3.32,P=.014)。
- rs2735839(19q13)风险等位基因与前列腺癌特异性死亡相关(HR 1.81/风险等位基因,95%CI 1.04-3.17,P=.037),而多基因风险评分无显著关联。
- 家族史与rs2735839风险等位基因联合与前列腺癌特异性死亡呈加性风险(HR 1.78/风险因素,95%CI 1.25-2.53,P=.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Family history and germline genetic risk single nucleotide polymorphisms (SNPs) have been separately shown to stratify lifetime risk of prostate cancer. Here, we evaluate the combined prognostic value of family history of prostate and other related cancers and germline risk SNPs among patients with favorable-risk prostate cancer. MATERIALS AND METHODS: A total of 1367 participants from the prospective Health Professionals Follow-up Study diagnosed with low- or favorable intermediate-risk prostate cancer from 1986 to 2017 underwent genome-wide SNP genotyping. Multivariable Cox regression was used to estimate the association between family history, specific germline risk variants, and a 269 SNP polygenic risk score with prostate cancer‒specific death. RESULTS: Family history of prostate, breast, and/or pancreatic cancer was observed in 489 (36%) participants. With median follow-up from diagnosis of 14.9 years, participants with favorable-risk prostate cancer with a positive family history had a significantly higher risk of prostate cancer‒specific death (HR 1.95, 95% CI 1.15-3.32, P = .014) compared to those without any family history. The rs2735839 (19q13) risk allele was associated with prostate cancer‒specific death (HR 1.81 per risk allele, 95% CI 1.04-3.17, P = .037), whereas the polygenic risk score was not. Combined family history and rs2735839 risk allele were each associated with an additive risk of prostate cancer‒specific death (HR 1.78 per risk factor, 95% CI 1.25-2.53, P = .001). CONCLUSIONS: Family history of prostate, breast, or pancreatic cancer and/or a 19q13 germline risk allele are associated with an elevated risk of prostate cancer‒specific death among favorable-risk patients. These findings have implications for how family history and germline genetic risk SNPs should be factored into clinical decision-making around favorable-risk prostate cancer.
引用
- Rumpf F, Plym A, Vaselkiv JB, et al. Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer. J Urol. 2024. PMID: 38598641. doi:10.1097/JU.0000000000003927
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。